At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 282 enrolled
Drug / intervention
Aficamten (5 mg, 10 mg, 15 mg, and 20 mg) +1 moredrug
Likely dose
Aficamten (5 mg, 10 mg, 15 mg, and 20 mg)from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Multi-Center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of CK-3773274 in Adults With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction
In Brief
A Phase 3 clinical trial evaluating Aficamten (5 mg, 10 mg, 15 mg, and 20 mg) and Placebo to match aficamten for Obstructive Hypertrophic Cardiomyopathy (oHCM). Completed, enrolled 282 participants across 114 sites in 14 countries.
Detailed Summary
The purpose of this study is to evaluate the efficacy and safety of aficamten (CK-3773274) versus placebo in adults with symptomatic hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract obstruction.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesChina, Czechia, Denmark, France, Germany, Hungary, Israel, Italy, Netherlands, Poland, Portugal, Spain, United Kingdom, United States
CollaboratorsCorxel Pharmaceuticals
Timeline
Phase 3CompletedFinished
20222023202420252026
First PostedJan 2022
Enrollment StartFeb 2022
Primary CompletionNov 2023
Study CompletionDec 2023
TodayJul 2026
First PostedJan 11, 2022
Enrollment StartFeb 1, 2022
Primary CompletionNov 10, 2023
Study CompletionDec 18, 2023
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 4.5 years ago
Interventions
Aficamten (5 mg, 10 mg, 15 mg, and 20 mg)drug
Aficamten tablets were administered orally once daily.
Placebo to match aficamtendrug
Placebo tablets were administered orally once daily.